Blau Farmacêutica First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Blau Farmacêutica (BVMF:BLAU3) First Quarter 2024 Results

Key Financial Results

• Revenue: R$359.7m (up 39% from 1Q 2023).
• Net income: R$40.1m (down 23% from 1Q 2023).
• Profit margin: 11% (down from 20% in 1Q 2023). The decrease in margin was driven by higher expenses.
• EPS: R$0.23 (down from R$0.29 in 1Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Blau Farmacêutica EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.0%. Earnings per share (EPS) exceeded analyst estimates by 28%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Global Biotechs industry.

Performance of the market in Brazil.

The company's shares are up 4.7% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Blau Farmacêutica that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.